AXLRx Book a callCommission

Companies

Company intelligence

Portfolio, pipeline and payer footprint for the innovator companies shaping each therapy area — grouped by tier. Innovators only: no generics, CDMOs or CROs.

Big Pharma

6 companies · Global innovators, multi-TA portfolios

Rare Disease · Oncology · Immunology · Cardiometabolic Novartis 7 AXLRx reports · View profile → Oncology · Rare Disease · Immunology · Cardiometabolic AstraZeneca 6 AXLRx reports · View profile → Metabolic · Neurology · Immunology · Oncology Eli Lilly 6 AXLRx reports · View profile → Metabolic · Rare Disease Novo Nordisk 6 AXLRx reports · View profile → Oncology · Immunology Merck 3 AXLRx reports · View profile → Immunology · Rare Disease · Oncology Sanofi 6 AXLRx reports · View profile →

Mid Specialty

5 companies · Focused specialty & rare-disease players

Immunology · Oncology Regeneron 4 AXLRx reports · View profile → Rare Disease Alexion (AZ Rare) 6 AXLRx reports · View profile → Metabolic Madrigal 3 AXLRx reports · View profile → Rare Disease BioCryst 3 AXLRx reports · View profile → Rare Disease Travere 3 AXLRx reports · View profile →

Small–Mid

3 companies · Single-asset & emerging innovators

Rare Disease Apellis 3 AXLRx reports · View profile → Rare Disease KalVista 3 AXLRx reports · View profile → Metabolic Akero 3 AXLRx reports · View profile →